Shetty Reshma P. has reported a series of stock transactions involving Ginkgo Bioworks Holdings, Inc. These filings, made on October 21, 2026, detail both acquisitions and sales of shares, reflecting an active management strategy within the life sciences sector.
Ginkgo Bioworks Holdings, Inc., known for its work in biological products, is publicly traded under the ticker symbol DNA. The company specializes in designing custom microbes for a variety of applications, positioning itself as a leader in the growing life sciences industry.
The recent filing outlines several transactions. On October 16, 2026, Shetty acquired 29,279 shares of Class A common stock and 10,619 shares of restricted stock units. Additionally, on the same day, she acquired 26,802 shares, bringing her total holdings to 465,701 shares following these transactions. On October 19, 2026, she sold 22,369 shares at a price of $10.143 per share, reducing her holdings to 453,951 shares.
These transactions may affect stakeholders, including investors and analysts, as they reflect Shetty's ongoing engagement with Ginkgo Bioworks. The active trading of shares could signal confidence in the company's future prospects, particularly in a competitive market focused on biological products.
Details were not available in the SEC filing regarding any upcoming events or further actions related to these transactions.